Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: LANCE B who wrote (66475)	10/6/2000 8:24:46 AM
From: y2kfree_radical	Read Replies (3) \| Respond to of 150070

DNAP-poor time to release such news imo

To: LANCE B who wrote (66475)	10/6/2000 9:25:16 AM
From: TomNY	Read Replies (1) \| Respond to of 150070

More info on DNAP news... Here's an Orchid news release from not too long ago announcing a sale to Bristol-Myers of the same system that DNAP just purchased: Orchid Announces Bristol-Myers Squibb Purchase of Turnkey SNPstream(TM) Genotyping Solution PRINCETON, N.J., July 19 /PRNewswire/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH - news) today announced that Bristol-Myers Squibb Company (NYSE: BMY - news) has signed a multi-year agreement to purchase Orchid's turnkey integrated SNPstream(TM) 25K solution for industrial-scale single nucleotide polymorphism (SNP) scoring. Bristol-Myers Squibb researchers will conduct high-throughput genotyping using Orchid's SNPstream 25K system and SNPware(TM) kits incorporating the company's patented SNP-IT(TM) primer extension biochemistries and software. Under terms of the agreement, Bristol Myers-Squibb will make an upfront payment to Orchid and will pay fees for SNPware consumables. Other financial details were not disclosed. ``With the arrival of the post-genomics era, the study of SNPs is accelerating as a foundation for understanding the medically useful aspects of genetic diversity. The selection of our turnkey SNPstream 25K genotyping solution by Bristol-Myers Squibb, one of the world's leading pharmaceutical companies, is further confirmation of the advantages of Orchid's integrated system consisting of our high throughput assay platform, easy-to-use SNP-IT-based genotyping kits and software,'' said Russell Granzow, vice president of marketing and business development of Orchid. ``We are delighted to add Bristol-Myers Squibb to our growing list of customers and partners.''